Phase 1 N=37 A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate
Phase 1
Primary: Dose of Metoprolol Resulting in no Change in Mean Heart Rate Over 24 Hours (M24HR) — 10.04; 60.95; 147.91 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=151 Addressing Drug Use Stigma in Human Immunodeficiency Virus (HIV) Care and Treatment Clinics in Tanzania
Drug Use Stigma in HIV Treatment Clinics
Primary: Modified Opening Minds Scale for Health Providers (OMS-HC) — 22.92; 16.82 score on a scale
N/A N=1,051 Shock, Whole Blood, and Assessment of TBI S.W.A.T. (LITES TO 2)
Hemorrhagic Shock · Traumatic Brain Injury
Primary: 4 Hour Mortality — 50; 32 Participants
Phase 2 N=80 A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
Metastatic Melanoma
Primary: Intracranial Objective Response Rate (ORR) — 46.4 Percentage of participants
N/A N=20 Renuvion APR System When Used as an Adjunct Procedure In Gynecomastia Surgery
Gynecomastia
Primary: Analysis of Bilateral Occurrence of Adverse Events — 42; 38; 6; 7 Number of Events
N/A N=207 Choosing an Effective Healthcare Spokesperson: An Interactive Intervention
Surrogate Decision-making · Healthcare Spokesperson · Advance Care Planning
Primary: Number of Participants Who Changed Their Choice of Spokesperson — 1 Participants
Phase 2 N=9 Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
Advanced Merkel Cell Carcinoma · Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 · Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Primary: Progression-free Survival (PFS) — 7.5; 5.5 months
N/A N=12 Substance P Challenge in Healthy Participants
Skin Diseases
Primary: Part 1: Wheal Response-time Area Under the Curve (AUC) Over the 2 Hours Post-challenge Period Following Skin Challenge With Substance P- at Challenge Visit 1 (Day 1)…
Phase 3 N=25,236 A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older
Respiratory Syncytial Viruses · Lower Respiratory Tract Disease
Primary: Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower…
Phase 3 N=204 Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Month 3 — 38.24; 5.88 Percentage of participants — p=<0.0001
Phase 2 N=12 Treatment of Women With Lipedema Involving Substantial Fat Knee of Women and Men With Nodular Dercum's Disease
Lipedema · Dercum Disease
Primary: The Incidence of Any Grade 3 or Greater Event Intolerable Side Effect Experienced in a Cohort — 0; 0; 0 Participants
Phase 1 N=160 A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531
Hepatitis B, Chronic
Primary: Part 1: Percentage of SAD Participants With Adverse Events (AEs) — 31.3; 25.0; 50.0; 25.0 percentage of participants
Phase 1 N=51 A Study of Mirikizumab (LY3074828) in Healthy Participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Phase 3 N=301 Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.
Acute Myeloid Leukemia
Primary: Percentage of Patients With Adverse Events (AEs), Grade 3 & 4 AEs, Serious Adverse Events (SAEs), AEs Leading to Discontinuation, and Deaths up to 24 Months (M24)…
Phase 4 N=57 Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Chronic Myelogenous Leukemia (CML) · Metastatic Gastrointestinal Stromal Tumors (GIST) · Acute Lymphoblastic Leukemia (ALL)
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 29; 15; 17; 2 Participants